Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AlumisALMS -1.48%12 3-Year EBITDA Growth Rate is -21.40% as of Mar. 2026. GuruFocus rates ALMS with a GF Score™ of 12/100. The stock has 6 warning signs investors should review. Among 1,137 Biotechnology companies, Alumis ranks worse than 86.28% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was -21.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 4 years, the highest 3-Year average EBITDA Per Share Growth Rate of Alumis was -21.40% per year. The lowest was -21.40% per year. And the median was -21.40% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Alumis 3-Year EBITDA Growth Rate Related Terms
ALMS vs ARQT, QURE, DYN: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Alumis's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alumis 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alumis's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Alumis's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of -21.40% mean?
Alumis (ALMS) has a 3-Year EBITDA Growth Rate of -21.40% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Alumis and its competitors. According to the industry distribution chart, Alumis ranks #981 out of 1137 companies in the Biotechnology industry, placing it in the top 86.3%.
Is Alumis' 3-Year EBITDA Growth Rate too high?
Alumis' current 3-Year EBITDA Growth Rate is -21.40%. Based on the distribution chart, Alumis ranks #981 out of 1137 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Alumis has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Alumis' 3-Year EBITDA Growth Rate compare to ARQT and QURE?
According to the Biotechnology industry distribution chart, Alumis ranks #981 out of 1137 companies for 3-Year EBITDA Growth Rate. This places Alumis in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,137 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Alumis and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alumis's current 3-Year EBITDA Growth Rate is -21.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alumis stock overvalued right now?
Alumis (ALMS) has a current 3-Year EBITDA Growth Rate of -21.40%. The current 3-Year EBITDA Growth Rate is -21.40%. Alumis' overall GF Score™ is 12/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Alumis (ALMS), the current 3-Year EBITDA Growth Rate is -21.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
12GF Score
Get the complete analysis for ALMS
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALMS has been successfully added to your 
